Key HighlightsPepGen (NASDAQ:PEPG) closed up 92.89% at about USD 4.61 on November 10, 2026, after trading more than 120% higher early in the session.In the FREEDOM2-DM1 Phase 2 trial, four monthly doses of PGN-EDODM1 at 10 mg/kg produced mean splicing correction of 46.5%, against …
Key HighlightsNet loss for the third quarter widened to USD 42.7 million, or USD 0.73 per share, from USD 24.6 million, or USD 0.54, in the third quarter of 2025, with noRevenuein either period.Operating expenses reached USD 44.7 million versus USD 20.3 million a …
In the second quarter of 2026, revenue grew 16% to USD 6.6 million, grossMarginwas 40.9% versus 43.9% because of tariffs, currency moves and a 4% revenue-sharing expense, and operating expenses were USD 6.9 million versus USD 9.1 million. Operating loss narrowed to USD 4.2 …
The improvement came from product changes rather than a hiring boom. Management said that hires and quits remained relatively flat year over year and quarter over quarter, so the labour market did not provide a tailwind. Instead, product changes designed to increase conversations between …
Second quarter 2026 revenue of USD 8.562 million rose 174% from about USD 3.1 million in the first quarter. GrossMarginwas 17.8% versus 20.3%, and non-GAAP gross margin was 26.2%. Operating expenses fell to USD 4.523 million from USD 5.901 million, and sales outside the …
Key HighlightsThird-quarterRevenuerose 64.9% to USD 21.6 million from USD 13.1 million, which the filing attributes to higher procedureVolumewith average revenue per procedure substantially constant.Net loss widened to USD 12.2 million, or USD 0.45 per share, from USD 8.5 million, or USD 0.40, while adjusted …
The filing says the global Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion lung cancer met its primary endpoint at interim analysis, with a statistically significant improvement in progression-free survival. Zipalertinib is co-developed with an affiliate of Taiho …
In the second quarter of 2026,Earningsfrom operations were USD 17.2 million, up 4%. US Midwest revenue rose 8% to USD 44.7 million, US West rose 16% to USD 23.4 million with Adjusted EBITDAR up 93% to USD 4.5 million, US East slipped 2% to …
Key HighlightsTSMC (NYSE:TSM) reported October 2026Revenueof TWD 586.89 billion, a monthly record, up 59.7% from a year earlier and 14.7% from September.Revenue for January through October reached about TWD 4.49 trillion, up 43.3% year over year.October sales, roughly USD 17.9 billion, already cover about …
Key HighlightsThird-quarterRevenuereached a record USD 146.3 million, up 14.9% and entirely organic, or 11.2% at constant currency, ahead of the company's outlook of at least USD 145.7 million.AdjustedGross Profitrose 24% to USD 53.5 million, lifting adjusted grossMarginto 36.6%, while adjusted EBITDA was USD 22.6 …